|Bid||3.6500 x 4000|
|Ask||4.9000 x 1000|
|Day's Range||3.6600 - 3.8000|
|52 Week Range||2.2600 - 7.5000|
|Beta (3Y Monthly)||3.74|
|PE Ratio (TTM)||39.15|
|Earnings Date||May 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.58|
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 28, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
The Italian Achromatopsia Association (IAA) today announced that it is organizing a trip to Pingelap, a remote Micronesian atoll in the South Pacific, also known as the “Island of the Color Blind.” While the incidence of achromatopsia, a rare inherited retinal disease (IRD), in the general population is 1 in every 30,000 individuals, the condition is found in between 10 and 30 percent of Pingelap’s population. The trip was made possible in part by a number of sponsors, including Applied Genetic Technologies Corporation (AGTC), a biotechnology company that is committed to developing transformational genetic therapies for patients suffering from rare diseases, including achromatopsia.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment of the third group in the dose escalation portion of its Phase 1/2 clinical trial evaluating the safety and efficacy of subretinal injection of (rAAV2tYF-PR1.7-hCNGA3) for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. “This achievement is another demonstration of our continued progress in the clinical development of our three product candidates for the treatment of X-linked retinitis pigmentosa and achromatopsia due to mutations in the CNGA3 or CNGB3 gene,” said Sue Washer, president and CEO of AGTC.
Sue Washer has been the CEO of Applied Genetic Technologies Corporation (NASDAQ:AGTC) since 2002. This analysis aims...
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join AGTC as Chief Medical Officer Brian Krex Named General Counsel GAINESVILLE, Fla. and.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 18, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.